MedTrace Logo

Validation of the Percentage of Alveolar Fibrocyte as Biomarker During ARDS

NCT01854424 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2017-03-22

No results posted yet for this study

Summary

Fibrocyte is a monocyte sub-population involved in fibroproliferation/repair processes and associated with outcome in different diseases. In previous study, we have demonstrated the presence of alveolar fibrocytes during Acute expiratory Distress Syndrome (ARDS) and their association with patient outcome. The purpose of this multicentric observational prospective study is to describe the percentage of alveolar fibrocytes in ICU patients with ARDS (survivors vs. non survivors) and to confirm their association with 28-day mortality.

Conditions

  • Acute Respiratory Distress Syndrome (ARDS)
  • Mechanical Ventilation

Interventions

OTHER

Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.

All the samples will be obtained during current care in the first week of evolution, and the last set of samples (BAL and blood sample between day 10-14) only in patients still under ventilation at this time point.

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Christophe Quesnel, MD, PhD · Assistance Publique

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-07-31
Completion
2016-07-11

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01854424 on ClinicalTrials.gov